

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NEUROCRINE BIOSCIENCES, INC.
Petitioner

v.

SPRUCE BIOSCIENCES, INC.
Patent Owner

U.S. Patent 12,569,491 B2

DECLARATION OF RAMESH THARUVAI, Ph.D.

IN SUPPORT OF PETITION FOR POST GRANT REVIEW OF U.S.
PATENT NO. 12,569,491 B2

I, Ramesh Tharuvai, Ph.D., declare as follows:

1. I have personal knowledge of the facts set forth in this declaration and could competently testify to them if called upon to do so.

2. I am the Vice President of Commercial Manufacturing and Supply Chain at Neurocrine Biosciences, Inc. (“Neurocrine”), a position I have held since 2016. In this role, I lead manufacturing, supply chain, and distribution operations for all of Neurocrine’s marketed products, including Crenessity®. I was personally involved in the launch of Crenessity® and in establishing its manufacturing and supply chain operations.

3. Crenessity® is manufactured, packaged, stored, and sold in the United States. The Crenessity® softgel dosage form is manufactured in St. Petersburg, Florida. The Crenessity® oral solution dosage form is manufactured in Harleysville, Pennsylvania. Both dosage forms are then packaged in Rockford, Illinois. The finished, packaged product is stored in Brooks, Kentucky prior to distribution and sale.

[intentionally left blank]

I declare under penalty of perjury that the foregoing is true and correct. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Executed on June 11, 2026 in San Diego, CA.



Ramesh Tharuvai, Ph.D.